Investopedia: Medicis May Not Stay Independent

There are a lot of interesting talking points to take from Medicis Pharmaceutical's (NYSE:MRX) latest earnings report. The company certainly does deserve praise for how it has managed potential generic threats to Solodyn, as well as arguably maximizing what it could from its LipoSonix business. Looking ahead, there is certainly the possibility that Medicis can become a more formidable competitor to Allergan (NYSE:AGN), but shareholders may want to consider the likelihood that Medicis will be folded into a larger pharmaceutical company in the not-so-distant future.

So-So Results for the Third Quarter  
Although there was no glaring problem area for Medicis, this quarter, it was still not all that strong. Revenue rose about 4%, and came in basically at the bottom end of the range. Growth in the core acne business was light (below 1%), while non-acne revenue rose 12% on strong unit sales of Restylane and Dysport.

Read more here:
http://stocks.investopedia.com/stock-analysis/2011/Medicis-May-Not-Stay-Independent-MRX-VRX-AGN-JNJ-WCRX-TEVA-SLTM-IPXL-MYL1110.aspx